In the context of HERV-K (HML-2), cell-based technologies such as autologous chimeric antigen receptor T (CAR-T) cells have been designed to specifically target HERV-K envelope protein, which is overexpressed on cancer cells but not on normal cells [155,156]. The gene discussed is CLEC10A; the disease is cancer.